

AF 1617  
H

Atty. Dkt. No. 016915-0244



61  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Gerd GEISSLINGER *et al.*

Title: USE OF R-ARYL PROPIONIC ACIDS FOR PRODUCING MEDICAMENTS TO TREAT DISEASES IN HUMANS AND ANIMALS, WHEREBY SAID DISEASES CAN BE THERAPEUTICALLY INFLUENCED BY INHIBITING THE ACTIVATION OF NF- $\kappa$ B

Appl. No.: 09/914,270

RECEIVED

Filing Date: 09/24/2001

MAR 08 2004

Examiner: M. Bahar

Art Unit: 1617

**AMENDMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

- [ X ] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a previous assertion of Small Entity status.
- [ ] Assertion of Small Entity status is enclosed.
- [ X ] The fee required for additional claims is calculated below:

	Claims As Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	19	-	20	= 0	x \$18.00 = \$0.00
Independents:	2	-	3	= 0	x \$86.00 = \$0.00
First presentation of any Multiple Dependent Claims:			+ \$290.00	=	\$0.00
			CLAIMS FEE TOTAL	=	\$0.00

[ X ] Applicants hereby petition for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

[ X ] Extension for response filed within the first month:	\$110.00	\$110.00
[ ] Extension for response filed within the second month:	\$420.00	\$0.00
[ ] Extension for response filed within the third month:	\$950.00	\$0.00
[ ] Extension for response filed within the fourth month:	\$1,480.00	\$0.00
[ ] Extension for response filed within the fifth month:	\$2,010.00	\$0.00
	<b>EXTENSION FEE TOTAL:</b>	<u>\$110.00</u>
[ ] Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$110.00	\$0.00
	<b>CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:</b>	<u>\$110.00</u>
[ X ]	Small Entity Fees Apply (subtract ½ of above):	<u>\$55.00</u>
	<b>TOTAL FEE:</b>	<u>\$55.00</u>

[ ] Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.

[ X ] A check in the amount of \$55.00 is enclosed.

[ X ] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date

3/1/04

By



FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5414  
Facsimile: (202) 672-5399

Richard L. Schwaab  
Attorney for Applicants  
Registration No. 25,479

Paul D. Strain  
Agent for Applicants  
Registration No. 47,369

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicant: Gerd GEISSLINGER *et al.*Title: USE OF R-ARYL PROPIONIC  
ACIDS FOR PRODUCING  
MEDICAMENTS TO TREAT  
DISEASES IN HUMANS AND  
ANIMALS, WHEREBY SAID  
DISEASES CAN BE  
THERAPEUTICALLY  
INFLUENCED BY INHIBITING  
THE ACTIVATION OF NF- $\kappa$ B

Appl. No.: 09/914,270

**RECEIVED**

Filing Date: 09/24/2001

MAR 08 2004

Examiner: M. Bahar

Art Unit: 1617

**AMENDMENT AND REPLY UNDER 37 CFR 1.116**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Final Office Action dated October 30, 2003, concerning the above-referenced patent application.

Applicants have enclosed with this amendment a Petition for Extension of Time to make this response timely.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this document.

**Remarks/Arguments** begin on page 5 of this document.